Strategic Acquisition Pelago Bioscience AB acquired RG Discovery AB on June 15, 2026, creating an integrated drug discovery partner spanning biology and chemistry. This signals a potential collaboration opportunity with Pelago’s expanded capabilities and RG Discovery’s CRO strengths, suggesting cross-sell of full-stack discovery services.

Integrated Capabilities RG Discovery combines drug discovery and analytical chemistry with advanced chemistry, macrocycles, and peptides. This presents a potential upsell to customers seeking end-to-end early discovery and analytical support, including ADME/physchem, medicinal chemistry, and specialized NMR/MS services.

Strategic Partnerships Existing collaborations with PolyPeptide Group and AI-driven partnerships indicate openness to co-development and funded projects. Leverage these relationships to propose expanded peptide chemistry, conjugates, and linkers, as well as AI-enabled data-driven discovery programs.

Regional Focus Based in Lund within Medicon Valley, RG Discovery serves Nordic and European clients with strengths in small molecules, macrocycles, and peptides. Use regional proximity to propose quick-start discovery sprints, localADME/biology support, and rapid regulatory-ready data packages.

Growth Signals Recent leadership addition in drug discovery and a history of project deliveries from hit finding to clinical candidates point to a scalable team capable of handling >1-2 concurrent programs. Position as a partner for late-stage hit-to-Candidate work, advanced MS/NMR analyses, and synthesis of complex chemistries to de-risk project timelines.